[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"carotid-stenosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:carotid-stenosis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,45,77,100,126,151,179,203,233,254,276,296,316,341,367,393,419],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100482766","multicentric-study-on-clopidogrel-resistance-in-dapt-for-cas-multi-resclosa-100482766",false,"NCT05566301","Multicentric Study on Clopidogrel Resistance in DAPT for CAS (MULTI-RESCLOSA)","MULTIcentric Study About RESistance to CLOpidogrel in Dual Antiplatelet Therapy for Carotid Stenting","Inclusion Criteria:\n\n* adult patients (age\\> 18 years)\n* patients who have given their consent to participate in the study, belonging to the U.O. of Vascular Surgery of the IRCCS Policlinico San Donato and the U.O. of Vascular Surgery of the participating centers and subjected to the treatment of carotid stenosis by stenting technique.\n\nExclusion Criteria:\n\n* underage patients\n* patients who have not given their consent to participate in the study,\n* patients who have carotid stenosis not susceptible to intervention by stenting\n* pregnant or lactating women (such as situations in which carotid stenting is contraindicated regardless of the execution of the study).","ALL","18 Years",{"count":19,"type":20},1140,"ESTIMATED","OBSERVATIONAL","Spontaneous prospective observational multicentre pharmacological study that aims to evaluate whether, from a statistical point of view, there is a significant difference between the use of Ticagrelor in \"non-responders\" patients to Clopidogrel undergoing carotid stenting and Clopidogrel in \"responders\" undergoing carotid stenting, in the onset of death and major adverse cardiovascular events (MACE) and bleeding events, 1 and 3 months after the procedure. Furthermore, the study aims to evaluate the possible preoperative clinical and pharmacological factors most associated with the phenomenon of resistance to Clopidogrel.\n\nInclusion criteria:\n\nThe data will be collected on adult patients (age\\> 18 years) who have given their consent to participate in the study, belonging to the U.O. of Vascular Surgery of the IRCCS Policlinico San Donato and the U.O. of Vascular Surgery of the participating centers and there subjected to the treatment of carotid stenosis by stenting technique.\n\nExclusion criteria:\n\nThose patients who are minors, who have not given their consent to participate in the study, or who have carotid stenosis not susceptible to intervention by stenting will be excluded from the study. Pregnant or lactating women will also be excluded from the study (such as situations in which carotid stenting is contraindicated regardless of the execution of the study).",[24,25],"Clopidogrel, Poor Metabolism of","Carotid Stenosis",[27,28,29,30,31],"clopidogrel resistance","carotid artery stenting","carotid stenosis","dual antiplatelet therapy","ticagrelor","RECRUITING","2026-07-01",{"date":35,"type":36},"2026-07-02","ACTUAL",{"date":38,"type":36},"2021-09-02",{"date":40,"type":20},"2030-12-31",{"name":42,"class":43},"IRCCS Policlinico S. Donato","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100638609","phase-3-alirocumab-for-stabilisation-of-symptomatic-vulnerable-carotid-plaque-100638609","NCT07586540","Alirocumab for Stabilisation of Symptomatic Vulnerable Carotid Plaque","Alirocumab for Stabilisation of Symptomatic Vulnerable Carotid Plaque: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial With High-Resolution Vessel-Wall MRI and Clinical Endpoints","CAROTID-STABIL","Inclusion Criteria:\n\n1. Age ≥ 40 and ≤ 80 years\n2. Recently symptomatic (TIA, amaurosis fugax, or non-disabling ischaemic stroke with mRS ≤ 2) referable to a carotid territory within 28 days of randomisation\n3. Ipsilateral extracranial internal carotid artery stenosis of 50-69% by NASCET criteria on CTA or DSA\n4. HR-VW-MRI evidence of IPH (MPRAGE hyperintensity ≥150% of adjacent sternocleidomastoid) OR LRNC ≥ 10% of plaque volume in the symptomatic plaque\n5. On a stable dose of high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) for ≥ 4 weeks, or able and willing to initiate atorvastatin 80 mg daily at randomisation\n6. LDL-C ≥ 70 mg\u002FdL (1.8 mmol\u002FL) at screening\n7. Able to undergo 3T MRI (no contraindications)\n8. Provides written informed consent\n\nExclusion Criteria:\n\n1. Indication for urgent carotid revascularisation within 14 days per treating team\n2. Disabling stroke (mRS \\> 2) or NIHSS \\> 5 at randomisation\n3. Carotid stenosis ≥ 70% or occlusion\n4. Cardioembolic stroke source (atrial fibrillation, LV thrombus, endocarditis, PFO with high-risk features)\n5. Intracranial haemorrhage within 12 months or any history of symptomatic ICH\n6. eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²\n7. Active hepatobiliary disease or ALT\u002FAST \\> 3x ULN\n8. Prior exposure to any PCSK9 inhibitor or inclisiran within 6 months\n9. Known hypersensitivity to alirocumab or excipients\n10. Pregnancy, breastfeeding, or unwillingness to use contraception in women of childbearing potential\n11. Life expectancy \\\u003C 24 months\n12. Participation in another interventional trial within 30 days\n13. Inability to comply with follow-up or MRI schedule","40 Years","80 Years",{"count":56,"type":20},280,"INTERVENTIONAL",[59],"PHASE3","CAROTID-STABILISE is a phase III, multicentre, randomised, double-blind, placebo-controlled trial evaluating whether alirocumab 150 mg subcutaneously every 2 weeks, added to high-intensity statin therapy, produces greater reduction in intraplaque haemorrhage (IPH) volume at 26 weeks compared with placebo in patients with recently symptomatic carotid stenosis of 50-69% harbouring IPH or lipid-rich necrotic core (LRNC) on high-resolution vessel-wall MRI. The study will enroll 280 participants across multiple centres with a 52-week extension for durability and clinical endpoints assessment.",[25],[63,64,65],"vulnerable plaque","alirocumab","PCSK9 inhibitor","NOT_YET_RECRUITING","2026-05-08",{"date":69,"type":36},"2026-05-14",{"date":71,"type":20},"2027-07",{"date":73,"type":20},"2030-09",{"name":75,"class":43},"Middle East North Africa Stroke and Interventional Neurotherapies Organization",14,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":57,"phases":87,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":44},"100624639","remote-ischemic-conditioning-plus-stenting-for-symptomatic-carotid-artery-stenosis-100624639","NCT07412249","Remote Ischemic Conditioning Plus Stenting for Symptomatic Carotid Artery Stenosis","Remote Ischemic Conditioning Plus Stenting for Symptomatic Carotid Artery Stenosis (RICSICAS): A Prospective, Randomized Controlled, Blind Endpoint, Single-Center Study","RICSICAS","Inclusion Criteria:\n\n* Age ≥ 40 years old;\n* Patients with symptomatic moderate to severe stenosis of the internal carotid artery;\n* History of ipsilateral cerebral ischemic symptoms within the past 180 days;\n* Planned for carotid artery stent;\n* Essen Score ≥ 3;\n* Modified Rankin Scale score of 0 or 1;\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Uncontrolled severe hypertension (systolic blood pressure \\> 180 mmHg or diastolic blood pressure \\> 110 mmHg despite medication)\n* Subclavian artery stenosis ≥ 50% or presence of subclavian steal syndrome\n* Severe hematological disorders or significant coagulation abnormalities\n* Contraindications to remote ischemic conditioning, such as severe soft tissue injury, fracture, or vascular injury in the upper limbs, or peripheral vascular disease in the distal upper limbs\n* Severe comorbid conditions with a life expectancy of less than 1 year\n* Participation in another clinical trial within the past 3 months or ongoing participation\n* Any other circumstances deemed by the investigator as unsuitable for participation in this clinical study.",{"count":86,"type":20},300,[88],"NA","Remote ischemic conditioning (RIC) has emerged as a promising non-invasive strategy to protect the brain, with evidence suggesting its benefit in patients with carotid artery stenting (CAS). However, the long-term benefit and safety of chronic RIC in this population remain unknown. This trial aims to evaluate whether chronic RIC reduces the incidence of major vascular events and improves clinical outcomes in high-risk patients with carotid artery stenosis who received CAS.",[25],"2026-03-30",{"date":93,"type":36},"2026-04-03",{"date":95,"type":36},"2026-03-04",{"date":97,"type":20},"2027-11-30",{"name":99,"class":43},"General Hospital of Shenyang Military Region",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":4,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":57,"phases":109,"briefSummary":110,"conditions":111,"keywords":112,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":44},"100266527","carotid-atherosclerosis--innovative-imaging-biomarkers-study-case-control-100266527","NCT02748941","Carotid Atherosclerosis : Innovative Imaging Biomarkers. Study Case-control","ACABII","Inclusion Criteria:\n\n* Carotid stenosis ≥ 50% NASCET\n* Case: ipsilateral carotid stenosis stroke, certified by MRI or CT in the preceding month, with no others causes of stroke\n* Control: no clinical sign or MRI hint for a recent stroke\n* Signed informed consent form\n* Patient affiliated to a social security system or equivalent\n\nExclusion Criteria:\n\n* Modified Rankin scale \\> 3\n* Homolateral stroke or TIA \\> 1 month\n* Medical history of homolateral carotid surgery, cervical radiation, carotid occlusive, homolateral intracranial stenosis, risk of developing arterial thromboembolic events\n* Renal failure (creatinine clearance \\\u003C 50 ml\u002Fmin)\n* Contraindication to ultrasound (sonovue)\n* Contraindication to MRI and its contrast media (Gadolinium)\n* Inability to sign informed consent\n* Inability to undergo any of the technics (claustrophobia…)\n* Serious co-morbid disease, dementia\n* Neurological disease with no carotid disease\n* Risk of pregnancy or pregnancy or breastfeeding\n* Adult under reinforced guardianship or legal guardian\n* Patient not understanding French",{"count":108,"type":20},77,[88],"Cerebrovascular accident (CVA) constitutes a major health public problem. This represents the second cardiovascular death cause. CVA is ischemic in 80% of cases. Atheroma of large arteries, mainly carotid, is involved in about 20% of cases.\n\nAfter several high grade studies (NASCET, ECST, ACAS, ACST), carotid surgery is based on stenosis calculation by Doppler ultrasound, CT angiography, MRI angiography or arteriography.\n\nThe composition of the plaque, showing its vulnerability, is associated with embolic risk and stroke. The therapeutic strategy based only on the narrowing of the arterial lumen is not satisfactory enough to prevent the occurrence of a transient ischemic attack (TIA) or an ipsilateral stroke due to carotid stenosis. Thus, new techniques emerge, to evaluate in vivo the inflammation of the plaque, its embolic consequences or the mechanical stress it undergoes. These techniques are: High Resolution MRI (HR MRI), evaluation of the Gray Scale Median (GSM) level, study of the plaque vascularization with Contrast Enhanced ultrasound (CEUS), High Intensity Transient Signals (HITS) by transcranial Doppler, micro RNA profile (mi RNA). These different modalities must be combined in order to increase the efficiency.\n\nBased on these encouraging results, the investigator aim at evaluating the ability of different methods or their combination to predict the occurrence of ischemic stroke or TIA due to emboli from a carotid atherosclerotic plaque. Before considering a cohort study, he investigator want to evaluate the performance of each of these new methods in the characterization of carotid plaque instability. Performance evaluation will allow us to choose secondarily the most relevant association.\n\nThe investigator propose, as a first step, to make a case-control study with these methods, the cases are patients who had an ischemic stroke (authenticated by both the clinical exam and brain MRI) on the same side as the carotid stenosis and the controls are patients with carotid stenosis but without ischemic stroke. This study is a cross-sectional study because it simultaneously measures the occurrence of the event (ischemic stroke) and the characteristics of the atheromatous plaque.\n\nOver a 2 year period, 45 symptomatic patients and 105 asymptomatic patients will be included with a carotid stenosis with at least a 50% caliber constriction according to NASCET criteria. (North American Symptomatic Carotid Endarterectomy Trial).",[25],[113,114,115,116,117,118],"unstable\u002Fstable atherosclerotic plaque","HITS","GSM","CEUS","HR MRI","mi-RNA",{"date":93,"type":36},{"date":121,"type":36},"2017-01-12",{"date":123,"type":20},"2027-02-12",{"name":125,"class":43},"Hospices Civils de Lyon",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":134,"conditions":135,"keywords":137,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":44},"100588923","research-on-ultrasound-diagnostic-criteria-for-intracranial-and-extracranial-arterial-serial-stenosis-100588923","NCT06947720","Research on Ultrasound Diagnostic Criteria for Intracranial and Extracranial Arterial Serial Stenosis","Inclusion Criteria:\n\n1. Patients diagnosed by carotid ultrasound with severe stenosis of the extracranial segment of the internal carotid artery or severe stenosis of the initial segment of the unilateral vertebral artery;\n2. Perform stent placement surgery within 2 weeks of ultrasound examination, and perform DSA and CTA examinations;\n3. Age ≥ 18 years old;\n4. Clinical data is complete.\n\nExclusion Criteria:\n\n1. Bilateral temporal windows are not transparent to sound;\n2. Patients with severe stenosis of the extracranial segment of the internal carotid artery have ipsilateral MCA occlusion\u002Fipsilateral common carotid artery severe stenosis or occlusion;\n3. Patients with severe stenosis of the extracranial segment of the internal carotid artery have severe stenosis of the contralateral carotid artery;\n4. Patients with severe stenosis or occlusion of the anterior circulation in the initial segment of unilateral vertebral artery;\n5. Severe stenosis or occlusion of bilateral subclavian arteries;\n6. Vasospasm caused by subarachnoid hemorrhage, etc;\n7. Related MCA or vertebral artery thrombolysis or endovascular treatment;\n8. Arrhythmias such as atrial fibrillation or heart failure that affect velocity measurement;\n9. CT, MRI, DSA examination contraindications or refusal of examination;\n10. Severe bleeding disorders or coagulation dysfunction;\n11. Merge serious diseases of other organs or tissues.",{"count":133,"type":20},700,"This study utilized different hemodynamic parameters of transcranial color-coded Doppler (TCCD) and transcranial Doppler (TCD) to conduct ultrasonic grading evaluation on middle cerebral artery (MCA) stenosis severity in patients with severe extracranial internal carotid artery stenosis, as well as intracranial V4 segment stenosis severity in patients with severe vertebral artery (VA) origin stenosis. The aim was to establish ultrasonic diagnostic criteria and provide reference basis for clinical treatment decision-making. Clarify the distribution of stroke risk factors, establish and evaluate stroke risk identification and prediction models. Patient cohort: Individuals undergoing carotid artery stenting or vertebral artery stenting, including those with either 1) severe extracranial internal carotid artery stenosis combined with ipsilateral MCA tandem stenosis, or 2) unilateral severe vertebral artery origin stenosis combined with intracranial V4 segment tandem stenosis. Collected data included demographic information, vascular ultrasound findings, and imaging examination results. All patients underwent a 1-year follow-up investigation documenting follow-up vascular ultrasound results, laboratory test results, imaging findings, clinical symptoms (ischemic stroke, transient ischemic attack, hemorrhagic stroke), and occurrence of endpoint events.",[136,25],"Ischemic Stroke",[138,139,140,141],"Serial stenosis","hemodynamics","Ultrasound diagnostic criteria","prediction model","2025-08-11",{"date":144,"type":36},"2025-08-15",{"date":146,"type":20},"2025-09-01",{"date":148,"type":20},"2027-06-30",{"name":150,"class":43},"Xuanwu Hospital, Beijing",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":158,"enrollmentInfo":159,"targetDuration":160,"studyType":21,"phases":4,"briefSummary":161,"conditions":162,"keywords":165,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":44},"100597346","residual-stenosis-and-restenosis-following-carotid-endarterectomy-with-primary-closure-a-prospective-tracking-study-100597346","NCT07057297","Residual Stenosis and Restenosis Following Carotid Endarterectomy With Primary Closure, A Prospective Tracking Study","RECEPT","Inclusion Criteria:\n\nPatients without matching any of exclusion criteria who underwent cartotid endarterectomy\n\nExclusion Criteria:\n\nAge ≤18 or ≥90 years\n\nPrevious endarterectomy or stenting\n\nUnsuitable vascular anatomy\n\nHigh perioperative risk\n\nContralateral cranial nerve X or XII palsy\n\nHistory of neck irradiation\n\nTandem carotid stenosis or intracranial vascular pathology (e.g., aneurysm or AVM)\n\nAbsence of signed informed consent","90 Years",{"count":86,"type":20},"1 Year","This prospective, multicenter observational study aims to evaluate the incidence, timing, and characteristics of residual and recurrent (restenosis) carotid artery stenosis following carotid endarterectomy (CEA) with primary closure. Conducted across several neurosurgical centers in the Czech Republic, the study will include patients undergoing elective CEA who meet standard clinical indications.\n\nParticipants will undergo preoperative CT angiography and follow-up imaging at 30 days and 1 year post-surgery. Residual stenosis is defined as ≥50% luminal narrowing detected within 30 days postoperatively, while restenosis is evaluated at later time points. The study will also assess clinical outcomes such as ischemic stroke, TIA, myocardial infarction, and mortality. The standardized surgical technique and harmonized diagnostic algorithm across all centers aim to provide robust data on the performance and durability of primary closure CEA.",[163,25,164],"Carotid Arteriosclerosis","Brain Stroke",[166,167,168,169],"Carotid Artery","Atherosclerosis","Endarterectomy","Stroke","2025-06-30",{"date":172,"type":36},"2025-07-09",{"date":174,"type":36},"2025-02-01",{"date":176,"type":20},"2027-01-01",{"name":178,"class":43},"Charles University, Czech Republic",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":188,"conditions":189,"keywords":190,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":44},"100188735","predictive-value-of-neovascularization-within-asymptomatic-carotis-stenosis-on-ceus-100188735","NCT01732523","Predictive Value of Neovascularization Within Asymptomatic Carotis Stenosis on CEUS","Predictive Value of Carotid Lesion Neovascularization Detected by Contrast-enhanced Ultrasound (CEUS) in Patients With Asymptomatic Carotid Stenosis","Inclusion Criteria:\n\n* Patients age \\> 18 years\n* Asymptomatic (no history of cerebrovascular event in the corresponding vessel territory) ≥30% carotid stenosis on standard carotid ultrasound\n\nExclusion Criteria:\n\n* History of previous carotid endarterectomy or carotid stenting.\n* Heart failure (HYHA III or IV)\n* Myocardial infarction (\\\u003C7d)\n* Severe pulmonal-arterial hypertension (pulmonal arterial pressure \\>90mmHg) based on clinical information (history of pulmonal arterial pressure, dyspnea on exertion New York Heart Association (NYHA) III and NYHA IV)\n* pregnancy (pregnancy test in patients of childbearing age: \\\u003C50 years and\u002For less than 2 years after menopause)\n* Follow-up is not considered feasible",{"count":187,"type":20},240,"Atherosclerosis is a chronic, systemic and progressive disease affecting different arterial blood vessels in the body. Atherosclerotic lesions silently progress from small plaques to severe stenosis and may remain asymptomatic for years. Unstable plaques and stenosis (also called vulnerable plaques), however, are prone to rupture leading to myocardial infarction, or stroke. The proliferation of the small arteries that are distributed to the outer and middle coats of the larger blood vessels (vasa vasorum) and within the atherosclerotic plaques (neovascularization) are inherently linked with the atherosclerotic plaque development, plaque inflammation and vulnerability. By injecting ultrasound contrast agents (microbubbles) into the blood stream, it is possible to detect this microcirculation of the vessel wall and the neovascularization within the atherosclerotic plaque using a contrast-enhanced ultrasound (CEUS) imaging technique. Particularly, CEUS of the carotid artery has been introduced as a non-invasive technique to improve detection of carotid atherosclerosis and to evaluate the presence of carotid plaque neovascularization which has emerged as a new marker for plaque vulnerability. The project investigates the predictive value of the detection of carotid plaque neovascularization on CEUS imaging in patients with asymptomatic carotid artery stenosis regarding the progression of the carotid atherosclerotic lesion and future vascular events including myocardial infarction, stroke or vascular intervention. The investigators hypothesize that neovascularization within the carotid lesion will significantly be more pronounced in patients with progressive carotid lesions and in patients suffering future vascular events during. The project will support the concept that intraplaque neovascularization is associated with plaque instability and vulnerability and therefore, the use of CEUS may provide an additional non-invasive, simple, safe, and reliable imaging modality to risk stratify individuals. The identification of vulnerable that are at increased risk of rupture by identification of intraplaque neovascularization is expected to improve the prediction of future vascular events and thus allow for better treatment selection. It will help the clinician to further risk stratify carotid stenosis. Particularly, it will help to identify unstable carotid stenosis that may already benefit from invasive therapy as carotid thromboendarterectomy and stenting.",[25],[191,192,193],"Carotid stenosis","Vasa Vasorum","Ultrasonography","2025-03-31",{"date":196,"type":36},"2025-04-03",{"date":198,"type":36},"2012-10",{"date":200,"type":20},"2027-12",{"name":202,"class":43},"University Hospital, Basel, Switzerland",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":211,"sex":16,"minAge":17,"maxAge":212,"enrollmentInfo":213,"targetDuration":4,"studyType":57,"phases":215,"briefSummary":216,"conditions":217,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":44},"100570266","monitoring-of-brain-metabolites-using-proton-and-deuterium-mr-techniques-100570266","NCT06705010","Monitoring of Brain Metabolites Using Proton and Deuterium MR Techniques","Non-Invasive Monitoring of Brain Metabolites Using Novel and Adapted Proton and Deuterium MR Techniques","SIGNATURES2023","General Inclusion Criteria (applicable to all groups):\n\n1. Signed informed consent by the participant.\n2. Ability to lie still in the MR scanner for at least one hour.\n3. No current or lifetime history of drug or alcohol abuse.\n4. No medications that interfere with cognition.\n5. Normal or corrected-to-normal vision.\n\nDisease-Specific Inclusion Criteria:\n\nI. Type 2 Diabetes Patients group (PG-IV-2H-DM):\n\n* Diagnosis of Type 2 diabetes according to the ADA classification.\n* Treatment with lifestyle modification and\u002For non-insulin agents.\n\nII. High-Grade Carotid Stenosis Patient Group (PG-IV-1H-HGCS):\n\n* ≥50% stenosis of the carotid artery.\n\nIII. Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD) Patients (PG-IV-2H-AD\u002FMCI):\n\n* Diagnosis of Mild Cognitive Impairment (MCI) or early Alzheimer's disease (AD).\n* Age range between 60-80 years.\n* Fluent in German.\n* Normal or corrected-to-normal vision and hearing.\n* Ability to understand the research and provide informed consent.\n\nExclusion Criteria:\n\n1. Under 18 years of age.\n2. Claustrophobia.\n3. Pregnancy or current state of lactation.\n4. Active implants (e.g., pacemakers, neuro-stimulators).\n5. Passive ferromagnetic implants.\n6. Passive non-ferromagnetic metallic implants \\> 4 cm in a region covered by the active radio frequency (RF) coils.\n7. Large tattoos inside a region covered by the active RF coils.\n8. Known or suspected non-compliance.\n9. Underweight \\\u003C30 kg body weight.\n10. Body mass index (BMI) \\> 30.\n11. Overweight \\>135 kg\n12. Persons with extreme big head circumference or extreme astigmatism, which cannot be corrected by MR-compatible eyeglasses.\n13. Persons not able to understand the informed consent form.\n14. Not agreeing with the institute's policy to inform the subject on incidental findings discovered during the examination.\n15. Visual and auditory acuity impairing neuropsychological testing (if relevant).\n16. Diabetes or glucose intolerance according to WHO recommendations (excluded in the diabetes patient group).\n17. Evidence of overt heart or renal disease.\n18. Evidence of gastrointestinal tract disease.\n19. Cognitive impairment (Mini-mental state examination score \\\u003C26\u002F30, CDR score \\>0, memory complaints) (excluding AD, MCI groups).\n20. Smoking.\n21. Current or life-time drug or alcohol abuse\n22. Untreated dyslipidemia, hypertension, or thyroid disease.\n23. Antidepressant medications with anticholinergic properties.\n24. Regular use of narcotic agents more than two doses per week within 4 weeks of screening.\n25. Antiparkinsonian medications used within 4 weeks of screening.\n26. Enrollment in any investigational drug studies within 4 weeks of screening.\n27. Immunomodulating or oncological treatment.\n28. Cardiac implantable electronic devices (CIED) such as pacemakers, implantable cardioverter defibrillators (ICDs), and cardiac resynchronization therapy (CRT) devices.\n29. Metallic intraocular foreign bodies: patients who have ever welded without eye protection or had facial injuries involving metal must have an orbit x-ray reviewed by a radiologist before MRI.\n30. Implantable neurostimulation systems.\n31. Cochlear implants\u002Fear implants.\n32. Drug infusion pumps (insulin delivery, analgesic drugs, or chemotherapy pumps).\n33. Catheters with metallic components (e.g., Swan-Ganz catheter).\n34. Metallic fragments (e.g., bullets, shotgun pellets, shrapnel).\n35. Cerebral artery aneurysm clips.\n36. Magnetic dental implants.\n37. Tissue expanders.\n38. Artificial limbs.\n39. Non-removable hearing aids.\n40. Non-removable piercings.\n41. Implantable cardiocerter defibrillators\n42. Cardiac resynchronization therapy devices\n43. Fever (temperature \\> 37.5°C measured prior to MRI).\n44. Volunteers taking amphetamines or sedatives",true,"130 Years",{"count":214,"type":20},140,[88],"MR pulse for whole brain optimal Deuterium (2H) Metabolic Imaging and EPSI (echo planar spectroscopic imaging) based SLOW-edited 1H-MRSI will be developed and optimized for use at an UHF scanner at 7 Tesla. The study has 4 phases.\n\nPhase I: The 2H and 1H MRSI sequences are developed and optimized in vitro (phantoms)\n\nPhase II: Sequences are applied in vivo in healthy volunteers and further optimized\n\nPhase III: Optimal 2H 1H pulse sequences are applied in 4 cohorts of healthy volunteers, to study the effect of aging with whole brain 2H and 1H MRSI.\n\nPhase IV: application of the sequences in 4 patient groups with different diseases: Alzheimer's diseases (AD) patients, diabetes mellitus type II (DM) patients, mild cognitive impaired (MCI) patients, and high grade carotid stenosis patients (HGCS).\n\nThe ultimate aim is to create for individual patient specific 3dimensional spatial resolved z-score maps (similar to FDG-PET) based on the healthy control data of phase III of the trial.",[218,219,25,220,221,222,223],"Aging","Brain Metabolic Disorder","Alzheimer Disease","Diabetes Type 2","Mild Cognitive Impairment","Brain Disease","2025-03-24",{"date":226,"type":36},"2025-03-25",{"date":228,"type":20},"2025-04-01",{"date":230,"type":20},"2028-03-31",{"name":232,"class":43},"Insel Gruppe AG, University Hospital Bern",{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":242,"conditions":243,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":44},"100583947","the-management-of-asymptomatic-carotid-stenosis-100583947","NCT06882954","The Management of Asymptomatic Carotid Stenosis","The Management of Asymptomatic Carotid Stenosis: Monocentric Experience","Inclusion Criteria:\n\n* Asymptomatic carotid stenosis\n* Patient with degree of carotid stenosis greater than 80% measured by the maximum systolic velocity at the site of the stenosis which must have been greater than 250 cm\u002Fs\n* Ultrasound characteristics of a possibly unstable plaque\n\nExclusion Criteria:\n\n* Symptomatic carotid artery stenosis",{"count":241,"type":20},500,"Carotid stenosis are asymptomatic if no hemispheric or retinal symptoms have appeared in the 6 months preceding the discovery of the stenosis. Asymptomatic carotid stenosis (ACS) accounts for about ¾ of all carotid lesions. The goal of treating carotid stenosis is to prevent a stroke. While carotid surgery is recommended in the elderly patients in cases of symptomatic carotid stenosis, that of ACS in patients over 75 years old, even when tight, remains subject to many controversies. Indeed, the debate, concerning the benefit to be expected from a surgical procedure or a possible angioplasty procedure, is not yet closed. The aim of our study, through a retrospective evaluation of the results of all consecutive carotid endarterectomy (CEA) and stenting in the participating center.",[244,25],"Carotid Artery Diseases","2025-03-15",{"date":247,"type":36},"2025-03-19",{"date":249,"type":36},"2019-01-01",{"date":251,"type":20},"2027-12-31",{"name":253,"class":43},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":258,"acronym":259,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":57,"phases":263,"briefSummary":265,"conditions":266,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":44},"100504585","phase-2-plaque-and-brain-inflammation-in-symptomatic-carotid-stenosis-role-of-the-ficolin-2-100504585","NCT05850247","Plaque and Brain Inflammation in Symptomatic Carotid Stenosis: Role of the Ficolin-2","STATEMENT","Inclusion Criteria:\n\n* Patients 18 years or over,\n* Signed written informed consent before any study specific intervention,\n* Probable ipsilateral transient ischemic attack (TIA - which involve a focal speech\u002Flanguage, motor or visual deficit referable to the distribution of a carotid artery and lasting less than 48 hours from the onset) OR retinal artery occlusion ≤ 48h OR ischemic stroke ≤ 48h from the onset,\n* Atherosclerotic carotid stenosis between 50% and 99% (NASCET method), as confirmed by one of the imaging examinations (among: Doppler ultrasound, MR angiography, CT angiography, catheter angiography) performed after index TIA or ischemic stroke\n* No other identified cause of TIA, ischemic stroke or retinal artery occlusion,\n\nExclusion Criteria:\n\n* Patients with inflammatory or autoimmune disease, hepatocellular insufficiency, acute or chronic infection, active malignancy, myocardial infarction or major surgery within the previous 30 days of index hospitalization according to the investigator,\n* Patients with severe renal insufficiency (estimated GFR \\\u003C 30 ml\u002Fmin at inclusion or known dialysis),\n* Patients with contraindication to MRI (agitation, claustrophobia, pacemaker, metallic (ferromagnetic) body, a known allergy to gadolinium) according to the investigator's judgment,\n* Patients with modified Rankin score greater than 3,\n* Patients currently enrolled in another clinical trial including investigational medicinal products,\n* Female patient who is pregnant or lactating, or is of child-bearing and who did not agree to use highly effective methods of birth control throughout the study,\n* Patient without health coverage,\n* Patient under legal protection",{"count":262,"type":20},20,[264],"PHASE2","Carotid artery stenosis is observed in about 3% of ≥ 60 years subjects and accounts for around 10-20% of all ischemic strokes. Beyond the degree of stenosis, plaque composition affects the risk of ischemic stroke. Identification of patients with vulnerable plaques at higher risk of stroke who might benefit from carotid revascularization is crucial.\n\nA growing body of evidence suggests that the lectin pathway of the complement system, and especially the ficolin-2, is involved in atherosclerosis. It has been hypothesized that circulating levels of ficolin-2 increase during chronic inflammatory conditions (i.e. growing atherosclerotic plaque) whereas they fall during sub-acute or acute inflammatory conditions (i.e. plaque rupture and acute ischemic stroke) because of consumption (binding to targets). Therefore, ficolin-2 has been proposed as a biomarker informing on the specific state of the plaque. However, in acute ischemic stroke due to carotid stenosis, both plaque rupture and stroke injury contribute to lectin pathway activation, thus affecting circulating levels of ficolin-2. Until now, the relative contribution of plaque and brain inflammation on circulating levels of ficolin-2 has not been documented.\n\nIn the present study the investigators aim to assess the association between circulating levels of ficolin-2 and carotid and brain inflammation on \\[18F\\]DPA-714 positron emission tomography (PET)\u002FMRI in patients with transient ischemic attack or acute ischemic stroke due to carotid stenosis. For that purpose, the investigators intend to include 30 patients with transient ischemic attack or acute ischemic stroke due to ≥ 50%. carotid stenosis. Each patient will have a measure of plasmatic level of ficolin-2 as well a \\[18F\\]DPA-714 PET\u002FMRI to quantify the fixation of the radiotracer on carotid and brain.",[267],"CAROTID STENOSIS","2025-02-03",{"date":270,"type":36},"2025-02-06",{"date":272,"type":36},"2024-02-13",{"date":274,"type":20},"2026-12-31",{"name":125,"class":43},{"id":277,"slug":278,"hasResults":11,"nctId":279,"briefTitle":280,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":284,"conditions":285,"keywords":286,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":292,"leadSponsor":294,"locationsCount":4},"100574213","efficacy-and-outcome-of-carotid-endarterectomy-for-symptomatic-carotid-stenosis-100574213","NCT06756360","Efficacy and Outcome of Carotid Endarterectomy for Symptomatic Carotid Stenosis","Inclusion Criteria:\n\n* • Symptomatic carotid artery stenosis\n\n  * Carotid artery stenosis more than 60 %\n\nExclusion Criteria:\n\n* Patient with other etiology (vasculitis dissection)\n\n  * Patient with mild Stenosis\n  * Asymptomatic",{"count":283,"type":20},25,"Neurovascular complications can result from this procedure usually from thromboembolism from the operated vessel, cerebral hypoperfusion causing ischaemia and, rarely, intracerebral haemorrhage. The overall incidence of perioperative strokes complicating CEA is approximately 4% ,and represents a devastating outcome that the procedure was designed to prevent. Other neurological sequelae complicating carotid revascularisation include cerebral hyperperfusion syndrome, cranial and peripheral nerve injuries, and contrast encephalopathy in patients undergoing CAS.\n\nThe aim of this study is To evaluate the safety and efficacy of carotid endarterectomy for symptomatic carotid Stenosis patients",[25],[287],"carotid endarterectomy","2025-01-01",{"date":290,"type":36},"2025-01-03",{"date":288,"type":20},{"date":293,"type":20},"2026-03-01",{"name":295,"class":43},"Assiut University",{"id":297,"slug":298,"hasResults":11,"nctId":299,"briefTitle":300,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":16,"minAge":302,"maxAge":4,"enrollmentInfo":303,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":304,"conditions":305,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":44},"100558103","selective-coronary-revascularization-in-carotid-artery-disease-patients-after-carotid-revascularization-scorecad-trial-100558103","NCT06546761","Selective Coronary Revascularization in Carotid Artery Disease Patients After Carotid Revascularization (SCORECAD Trial)","Inclusion Criteria:\n\n1. Inform consent obtained before any study-related activities;\n2. Age above or equal to 50 years with symptomatic or asymptomatic critical carotid stenosis (symptomatic patients with at least Rankin III) which has been successfully revascularized by carotid endarterectomy or stenting within the past 14 days;\n3. Willing and able to undergo coronary CTA scan within 14 days of randomization and agrees to submission of CTA data set for HeartFlow FFRct analysis with results made available to treating physician.\n\nExclusion Criteria:\n\n1. Known CAD, history of MI, prior coronary revascularization (PCI or CABG);\n2. Patient underwent coronary angiography or coronary CTA before the randomization;\n3. Known history of 2nd or 3rd degree heart block; sick sinus syndrome; long QT syndrome;\n4. History of severe asthma, severe or bronchodilator-dependent Chronic obstructive pulmonary disease (COPD);\n5. Severe congestive heart failure (NYHA III or IV);\n6. Severe arrhythmia, prior pacemaker or internal defibrillator lead implantation;\n7. Impaired chronic renal function (EPI-GFR\\\u003C30ml\u002Fmin);\n8. Subjects with known anaphylactic allergy to iodinated contrast;\n9. Pregnancy or unknown pregnancy status in subject of childbearing potential;\n10. Evidence of ongoing or active clinical instability, including acute chest pain (sudden onset), cardiogenic shock, unstable blood pressure with systolic blood pressure \\\u003C90 mmHg, or acute pulmonary edema;\n11. Any active, serious, life-threatening disease with a life expectancy of less than 2 years;\n12. Any active infection;\n13. Inability to comply with study procedures;\n14. Contraindication for guideline-guided long-term antiplatelet\u002Fanticoagulation regime after PCI\u002FCABG;\n15. Large neurologic deficit (Rankin scale \\>III);\n16. Participation in any interventional clinical study within 30 days prior to screening.","50 Years",{"count":86,"type":20},"The primary objective of this study is to determine whether among symptomatic and asymptomatic carotid artery stenosis (CAS) patients with no known coronary artery disease (CAD) who had undergone carotid artery revascularization (endarterectomy of stenting) a strategy of best medical therapy (BMT) plus selective coronary revascularization based on FFRct assessment of lesion-specific coronary ischemia can reduce adverse cardiac events and improve survival compared to BMT alone. Lesion-specific coronary ischemia is defined as FFRCT ≤0.80 distal to stenosis in a major (≥2 mm) coronary artery with severe ischemia defined as FFRCT ≤0.75.",[25,306],"Coronary Artery Disease","2024-08-06",{"date":309,"type":36},"2024-08-09",{"date":311,"type":36},"2024-06-25",{"date":313,"type":20},"2029-06-25",{"name":315,"class":43},"Pauls Stradins Clinical University Hospital",{"id":317,"slug":318,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":323,"enrollmentInfo":324,"targetDuration":4,"studyType":57,"phases":326,"briefSummary":327,"conditions":328,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":4},"100514568","cognitive-improvement-after-carotid-stenting-in-hyperbaric-oxygen-therapy-trial-100514568","NCT05980195","Cognitive Improvement After Carotid Stenting in Hyperbaric Oxygen Therapy Trial","Cognitive Improvement After cARotid stEnting in HyperBaric Oxygen Therapy Trial (CARE-HBOT)","Inclusion Criteria:\n\n1. Age from 18 to 75 years\n2. National Institute of Health stroke scale (NIHSS) ≤3\n3. Culprit vessel was the common carotid artery or extracranial internal carotid artery, involving or not involving the external carotid artery\n4. The degree of culprit arterial stenosis is 70-99 % ; based on Digital subtraction angiography (DSA) (According to North American Symptomatic Carotid Endarterectomy Trial (NASCET) method)\n5. The diameter of the target vessel between 4.0 mm - 9.0 mm\n6. Mini-mental State Examination (MMSE) score : education level-middle school ≤ 24; education level-high school ≤ 20 ; education level-college ≤ 17\n7. Baseline modified Rankin Scale (mRS) score ≤ 3\n8. Patient understands the purpose and requirements of the study, and has provided informed consent\n\nExclusion Criteria:\n\n1. Tandem extracranial or intracranial stenosis (70%-99%) or occlusion that is proximal or distal to the target intracranial lesion\n2. Serious perioperative complications affecting subsequent hyperbaric oxygen therapy (such as cerebral hemorrhage, disabling stroke, etc.)\n3. Any history of brain parenchymal or subarachnoid, subdural or extradural haemorrhage in the past 12 months\n4. Hemorrhagic transformation after ischemic stroke within 60 days before enrollment\n5. Intracranial artery stenosis caused by non-atherosclerotic lesions, including: arterial dissection, Moyamoya disease, vasculitis disease, herpes zoster, varicella-zoster or other viral vascular diseases, neurosyphilis, any other intracranial infections, any intracranial stenosis related to cerebrospinal fluid cells, radiation-induced vascular disease, fibromuscular dysplasia, sickle cell disease, neurofibromatosis, central nervous system benign vascular disease, postpartum vascular disease, suspected vasospasm, suspicious embolism recanalization, etc\n6. Nervous system diseases in the past two years, characterized by transient or fixed neurological deficits (such as partial or secondary generalized seizures of epilepsy, complex or classic migraine, tumor or other intracranial space-occupying lesions, subdural hematoma, brain contusion or other post-traumatic lesions, intracranial infection, demyelinating diseases, intracranial hemorrhage, etc.), which cannot be distinguished from cerebral infarction\n7. History of stenting of an intracranial or extracranial artery\n8. Presence of any unequivocal cardiac source of embolism\n9. Chronic atrial fibrillation; paroxysmal atrial fibrillation or paroxysmal atrial fibrillation in the past 6 months, or a history of paroxysmal atrial fibrillation, requiring long-term anticoagulation\n10. Myocardial infarction in the past 30 days\n11. Combined with intracranial tumor, aneurysm or intracranial arteriovenous malformation\n12. Cannot tolerate dual antiplatelet therapy due to known diseases (such as gastrointestinal bleeding)\n13. Contraindications to heparin, aspirin, clopidogrel, ticagrelor, anesthesia, or contrast agents\n14. Hemoglobin\\\u003C100g\u002FL, platelet count \\\u003C100×109\u002FL, international normalized ratio (INR)\\>1.5, or heparin-related thrombocytopenia or uncorrectable factors leading to bleeding\n15. Not suitable for vessel angiography or endovascular interventional therapy (such as morbid obesity; serious vascular tortuosity that hinders the safe introduction of the guiding catheter)\n16. Severe hepatic and renal dysfunction\n17. Major surgery within the past 30 days or planned within 90 days\n18. Renal artery, iliac artery, and coronary artery requiring simultaneous intervention\n19. Life expectancy \\\u003C1 year\n20. Pregnant or lactating women\n21. Cognitive assessment and follow-up could not be completed due to factors such as severe aphasia, neuropsychological illness or mental illness or dysarthria and inability to communicate\n22. History of drug or alcohol abuse, head trauma or central nervous system infection; current use of drugs that affect cognition\n23. Combined with diseases that are not suitable for hyperbaric oxygen therapy (such as untreated pneumothorax, uncontrolled epilepsy, claustrophobia, angle-closure glaucoma, cavitary pulmonary tuberculosis, etc.)\n24. Enrollment in another study that would conflict with the current study","75 Years",{"count":325,"type":20},90,[88],"The purpose of CARE-HBOT study is to evaluate whether patients with symptomatic severe carotid artery stenosis with cognitive impairment who underwent hyperbaric oxygen therapy plus standard medical treatment after stent implantation could improve their cognitive function compared with those who underwent standard postoperative medical treatment.",[25,329,330,331],"Cognitive Impairment","Hyperbaric Oxygen Therapy","Stent Implantation","2024-07-17",{"date":334,"type":36},"2024-07-18",{"date":336,"type":20},"2024-07-16",{"date":338,"type":20},"2025-12-31",{"name":340,"class":43},"Beijing Tiantan Hospital",{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":347,"eligibilityCriteria":348,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":57,"phases":351,"briefSummary":352,"conditions":353,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":44},"100555361","phase-3-carotid-artery-stenting-during-endovascular-treatment-of-acute-stroke-100555361","NCT06511089","Carotid Artery Stenting During Endovascular Treatment of Acute Stroke","Carotid Artery Stenting During Endovascular Treatment of Acute Ischemic Stroke: A Randomized Multicenter Clinical Trial in Patients With Acute Ischemic Stroke and Carotid Artery Stenosis Undergoing Endovascular Treatment","CASES","Inclusion Criteria:\n\n1. Acute ischemic stroke due to proximal intracranial occlusion in the anterior circulation (intracranial ICA, M1, proximal M2) on the CT angiography\n2. Stenosis \\>50% according to the NASCET criteria16 or initial occlusion of the ipsilateral cervical carotid artery of presumed atherosclerotic origin on baseline CT angiography\n3. Eligible for EVT according to the guidelines: EVT within 6 hours of onset or EVT between 6-24 hours after onset based on perfusion CT imaging selection (conform current guidelines)\n4. Baseline National Institute of Health Stroke Scale (NIHSS) score ≥2\n5. Age \\>18 years\n6. Written informed consent (deferred consent)\n\nExclusion Criteria:\n\n1. Any intracranial hemorrhage\n2. Cervical carotid artery stenosis or occlusion with other causes than presumed atherosclerosis (e.g. carotid artery dissection, floating thrombus, carotid web)\n3. Any exclusion criterion for EVT according to the guidelines\n4. Pre stroke disability (defined as a modified Rankin Scale score \\>2)\n5. Recent gastro-intestinal or urinary tract hemorrhage (\\\u003C6 weeks)\n6. Recent severe head trauma (\\\u003C6 weeks)\n7. Recent infarction on baseline brain CT in the same vascular territory (\\\u003C6 weeks)\n8. Known allergy to aspirin and\u002For clopidogrel\n9. Pregnancy",{"count":350,"type":20},600,[59],"Rationale: Approximately 20% of the patients with acute ischemic stroke due to an intracranial large vessel occlusion (LVO) has a high-grade stenosis in the ipsilateral cervical carotid artery. It is uncertain whether immediate carotid artery stenting (CAS) of a cervical carotid artery stenosis during endovascular thrombectomy (EVT) is beneficial. Immediate CAS could improve cerebral perfusion and prevent recurrent ischemic stroke but could also increase the chance of intracranial hemorrhagic complications due to hyperperfusion syndrome or to the required antiplatelet treatment to prevent stent occlusion. Moreover, some patients end up with a severe disabling stroke after EVT. In these patients carotid revascularization by carotid endarterectomy (CEA) or CAS would usually not be performed but these patients would be treated by medical management only.\n\nObjective: to assess the safety and efficacy of immediate cervical CAS during EVT in patients with acute ischemic stroke due to LVO with a high-grade stenosis \\>50% or occlusion of the ipsilateral cervical carotid artery.\n\nStudy design: prospective randomized open label controlled trial comparing immediate CAS during EVT versus EVT with deferred treatment of the cervical carotid artery lesion (deferred CAS\u002FCEA or medical management alone). Outcome assessment will be blinded for treatment allocation.",[354,355,25,356,357],"Stroke, Acute","Stroke, Ischemic","Carotid Atherosclerosis","Carotid Occlusion","2024-07-15",{"date":360,"type":36},"2024-07-19",{"date":362,"type":36},"2022-11-15",{"date":364,"type":20},"2026-11-15",{"name":366,"class":43},"University Medical Center Groningen",{"id":368,"slug":369,"hasResults":11,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":373,"eligibilityCriteria":374,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":375,"targetDuration":4,"studyType":57,"phases":377,"briefSummary":378,"conditions":379,"keywords":380,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":44},"100382580","endovascular-acute-stroke-intervention---tandem-occlusion-trial-100382580","NCT04261478","Endovascular Acute Stroke Intervention - Tandem OCclusion Trial","A Multi-centre, Prospective, Randomized, Open-label, Blinded Endpoint (PROBE) Controlled Trial Comparing Cervical Internal Carotid Artery Stenting to no Stenting During Thrombectomy for Tandem Occlusion Stroke","EASI-TOC","Inclusion Criteria:\n\n* Acute ischemic anterior circulation stroke eligible for endovascular therapy according to local guidelines, with or without prior intravenous thrombolysis:\n\n  * Occlusion of the carotid terminus, M1 or M2 segments of the middle cerebral artery (MCA)\n  * A neurological deficit judged to be disabling by the patient and\u002For treating physician\n  * Any acute imaging judged by the treating physician to demonstrate salvageable brain tissue possibly amenable to EVT\n  * Groin puncture within 24-hours of onset or last known normal\n* Tandem ipsilateral high-grade (≥70%) cervical internal carotid artery (ICA) stenosis or occlusion of presumed atherosclerotic etiology on initial non-invasive vascular imaging\n* Informed consent from patient or surrogate or deferral of consent, according to local ethics policies\n\nExclusion Criteria:\n\n* Pre-existing neurological impairment (modified Rankin score ≥3)\n* Any underlying disease or condition making protocol adherence and\u002For 3-month follow-up unlikely\n* Any known contra-indication to EVT, angioplasty\u002Fstenting, or antiplatelet therapy\n* Tandem ipsilateral high-grade (≥70%) cervical internal carotid artery (ICA) stenosis or occlusion NOT confirmed on conventional angiography\n* Ipsilateral ICA stenosis or occlusion attributable to clinically or radiologically confirmed arterial dissection\n* Isolated cervical carotid occlusion without intracranial occlusion\n* Pregnancy",{"count":376,"type":20},458,[88],"Patients with tandem occlusion or tandem lesion (TL), that is, stroke with an acute intracranial anterior circulation occlusion and an ipsilateral cervical ICA (c-ICA) high-grade stenosis or occlusion, constitute about 15-20% of patients undergoing endovascular thrombectomy (EVT).\n\nHowever, the optimal treatment of acute stroke patients with TL remains uncertain, as relatively few patients with TL were included in the major randomized controlled trials of EVT and management of the c-ICA was generally not specified by protocol nor analyzed post-hoc.\n\nRecent large multi-centre retrospective cases series suggest that acutely stented patients may have more favorable outcomes than patients treated with angioplasty alone or those with no acute ICA intervention, but high quality randomized trial data are lacking.\n\nEASI-TOC, a phase 3, academic multi-centre, controlled trial (PROBE design) with embedded pilot phase, will seek to determine if in patients undergoing acute intracranial thrombectomy for anterior circulation stroke with concurrent ipsilateral symptomatic high-grade (≥70%) atherosclerotic stenosis or occlusion of the extracranial ICA, endovascular ICA revascularization with stenting is superior to intracranial thrombectomy alone with regards to functional outcome at 90 days. Patients will be randomized to Acute stenting or No acute stenting (1:1 allocation).",[354,25,244],[381,382,383],"Thrombectomy","Tandem occlusion","Carotid stenting","2023-11-14",{"date":386,"type":36},"2023-11-18",{"date":388,"type":36},"2020-08-31",{"date":390,"type":20},"2027-03",{"name":392,"class":43},"Centre hospitalier de l'Université de Montréal (CHUM)",{"id":394,"slug":395,"hasResults":11,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":399,"eligibilityCriteria":400,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":401,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":402,"conditions":403,"keywords":405,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":44},"100458494","transcranial-doppler-cerebral-blood-flow-and-cognitive-impairment-in-heart-failure-100458494","NCT05250349","TRAnscranial Doppler CErebral Blood Flow and Cognitive IMPAIRment in Heart Failure","TRAnscranial Doppler CErebral Blood Flow and Cognitive IMPAIRment in Patients With Heart Failure and Presence\u002FAbsence of Atherosclerotic Carotid Artery Stenosis","TRACE-IMPAIR","Inclusion Criteria:\n\n* Clinically stable patients (NYHA I-III symptoms) with HF (for at least 6 months) either of ischemic or inflammatory etiology as well as genetic cardiomyopathies\n* Signed informed consent form\n* Consent to imaging studies: echocardiography, carotid and transcranial Doppler sonography and neuropsychological tests (MMSE and MoCA).\n\nExclusion Criteria:\n\n* Co-existing, severe, irreversible disease (e.g. advanced cancer)\n* Previously diagnosed dementia (including severe dementia - MMSE and MoCA score \\\u003C10)\n* Psychiatric condition which may influence cognitive function\n* Acute, decompensated HF\n* Reversible cause of HF - tachyarrhytmic, peripartum or toxic cardiomyopathy, acute myocarditis, acute myocardial infarction\n* Aortic stenosis\n* Cerebral stroke in the preceding 3 months\n* Lack of transcranial Doppler acoustic window\n* Echocardiographic projections precluding adequate measurements\n* Anemia with Hemoglobin \\\u003C 8 g\u002Fdl\n* Alcohol or psychoactive agents abuse",{"count":86,"type":20},"TRACE-IMPAIR is a prospective, clinical study of consecutive patients that evaluates the relationship between heart failure (HF) and cognitive impairment in relation to carotid and cerebral flow. The carotid and cerebral flow will be assessed using Doppler ultrasonography, and cognitive function will be estimated during routine neuropsychological tests.\n\nIt is an observational, three(natural)-group, single-center study. It is also an Academic Registry - the scientific activity of the Faculty of Medicine, Collegium Medicum, Jagiellonian University, and John Paul II Hospital.",[404,329,25],"Heart Failure",[25,404,406,407,408,329,409],"Carotid Doppler","Transcranial Doppler","Cerebral Flow","Stroke Volume","2022-02-10",{"date":412,"type":36},"2022-02-22",{"date":414,"type":36},"2021-09-01",{"date":416,"type":20},"2027-09-01",{"name":418,"class":43},"John Paul II Hospital, Krakow",{"id":420,"slug":421,"hasResults":11,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":425,"eligibilityCriteria":426,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":427,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":429,"conditions":430,"keywords":434,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":446,"locationsCount":44},"100437231","simultaneous-cardiac-surgery-and-micronet-covered-stent-carotid-revascularization-in-high-perioperative-stroke-risk-patients-100437231","NCT04973579","Simultaneous Cardiac Surgery and Micronet-covered Stent Carotid Revascularization in High Perioperative Stroke Risk Patients","SIMultaneous Urgent Cardiac Surgery and Endovascular Stroke Prevention Using the Micronet-covered CGUARD Stent in Hemodynamically Compromised Patients at Increased Peri-operative Stroke Risk: SIM-GUARD Study","SIM-GUARD","Inclusion Criteria:\n\n* Patients eligible for concomitant carotid artery stenting in conjunction with cardiac surgery based on Heart Team and NeuroVascular Team reccomendation and according to local standards of practice.\n* Signed informed consent form\n* Consent to (routinely performed in this group of patients) follow-up visits and tests performed (routinely) during long-term follow-up\n* De novo atherosclerotic lesions or neo-atherosclerosis.\n* Symptomatic patients (with a history of ipsilateral transient cerebral ischemia, stroke or amaurosis fugax within the past 6 months) with carotid artery stenosis ≥50% as assessed by NASCET angiography or\n* Asymptomatic patients with carotid artery stenosis ≥70-80% as assessed by angiography (NASCET method).\n* Coronary angiography-confirmed multivessel disease or left main stem stenosis with the symptoms of unstable angina or non-ST-segment elevation myocardial infarction.\n* Severe symptomatic valvular disease detected by echocardiography.\n\nExclusion Criteria:\n\n* Expected survival time \\\u003C1 year (e.g., cancer).\n* Renal failure with GFR \\\u003C 20 ml\u002Fmin\u002F1.73 m2 as calculated by the CKD-EPI formula\n* Women who are pregnant (pregnancy test).\n* Coagulopathies.\n* History of hypersensitivity to a contrast agent that does not respond to pharmacotherapy.\n* Total carotid artery occlusion.\n* Stent in the carotid artery that protrudes into the aortic arch.\n* Anatomic variants that preclude stent implantation.\n* Significant stenosis of the common carotid artery proximal to the target lesion.\n* Mobile atherosclerotic plaques in the aortic arch.\n* Anatomy of the coronary arteries unsuitable for bypass grafting.\n* Lack of available vascular material for grafting.\n* Porcelain aorta.",{"count":428,"type":20},50,"Prospective, single-center, clinical registry of patients with symptomatic\u002Fcritical carotid artery stenosis at risk of stroke coexisting with unstable or multivessel severe coronary artery disease and\u002For severe valvular heart disease undergoing endovascular treatment of carotid atherosclerosis using a mesh stent in combination with cardiac surgery (coronary artery bypass grafting (CABG) and\u002For valve surgery). A study involving clinical data evaluation of truly simultaneous treatment outcomes in patients deemed to require carotid revascularization at the time of surgical cardiac intervention (single-stage, simultaneous treatment). An open-label study, without randomization - a single arm study.\n\nAcademic Registry - scientific activity of the Faculty of Medicine, Collegium Medicum, Jagiellonian University and John Paul II Hospital.",[25,306,431,432,433],"Valvular Heart Disease","Myocardial Infarction","Pulmonary Edema With Heart Failure",[25,435,436,437,438],"Coronary Artery Disease, Valvular Disease","Heart Failure, Pulmonary Edema","Single Anesthesia","Simultaneous Procedure","2021-07-13",{"date":441,"type":36},"2021-07-22",{"date":443,"type":36},"2021-05-01",{"date":445,"type":20},"2027-05-01",{"name":418,"class":43}]